CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
CS Diagnostics Corp. (OTCQB:CSDX) has received a Letter of Intent from SAN ART CAPITAL SAS for a proposed $5 million equity loan in exchange for Series C Preferred Stock. The funding agreement aims to support the production and commercialization of CS Diagnostic's assets, particularly the CS-Protect Hydrogel and MEDUSA products in global markets.
The funds will be allocated to support the commercial rollout of CS-Protect Hydrogel, further R&D, operational expansions, and obtaining U.S. EPA approval for the Smart Disinfectant Product MEDUSA. The parties are proceeding with final due diligence and definitive agreement negotiations, targeting closure in the coming weeks.
CS Diagnostics Corp. (OTCQB:CSDX) ha ricevuto una Lettera di Intenti da parte di SAN ART CAPITAL SAS per un prestito azionario di 5 milioni di dollari in cambio di azioni privilegiate di Serie C. L'accordo di finanziamento mira a sostenere la produzione e la commercializzazione degli asset di CS Diagnostics, in particolare i prodotti CS-Protect Hydrogel e MEDUSA nei mercati globali.
I fondi saranno destinati a supportare il lancio commerciale di CS-Protect Hydrogel, ulteriori attività di ricerca e sviluppo, espansioni operative e l'ottenimento dell'approvazione EPA statunitense per il prodotto disinfettante intelligente MEDUSA. Le parti stanno procedendo con la due diligence finale e le negoziazioni per l'accordo definitivo, puntando alla chiusura nelle prossime settimane.
CS Diagnostics Corp. (OTCQB:CSDX) ha recibido una Carta de Intención de SAN ART CAPITAL SAS para un préstamo de capital de 5 millones de dólares a cambio de acciones preferentes Serie C. El acuerdo de financiamiento tiene como objetivo apoyar la producción y comercialización de los activos de CS Diagnostics, en particular los productos CS-Protect Hydrogel y MEDUSA en los mercados globales.
Los fondos se destinarán a respaldar el lanzamiento comercial de CS-Protect Hydrogel, más investigación y desarrollo, expansiones operativas y la obtención de la aprobación de la EPA de EE.UU. para el producto desinfectante inteligente MEDUSA. Las partes están avanzando con la diligencia debida final y las negociaciones del acuerdo definitivo, con la intención de cerrar en las próximas semanas.
CS Diagnostics Corp. (OTCQB:CSDX)는 SAN ART CAPITAL SAS로부터 5백만 달러 규모의 지분 대출에 대한 의향서를 받았습니다. 이는 시리즈 C 우선주와 교환하는 조건입니다. 이번 자금 조달 계약은 CS Diagnostics의 자산, 특히 CS-Protect Hydrogel과 MEDUSA 제품의 글로벌 시장 생산 및 상용화를 지원하는 것을 목표로 합니다.
자금은 CS-Protect Hydrogel의 상업적 출시 지원, 추가 연구개발, 운영 확장, 그리고 스마트 소독제 제품인 MEDUSA의 미국 EPA 승인 획득에 사용될 예정입니다. 양측은 최종 실사와 최종 계약 협상을 진행 중이며, 몇 주 내에 마무리할 계획입니다.
CS Diagnostics Corp. (OTCQB:CSDX) a reçu une lettre d'intention de SAN ART CAPITAL SAS concernant un prêt en actions de 5 millions de dollars en échange d'actions privilégiées de série C. Cet accord de financement vise à soutenir la production et la commercialisation des actifs de CS Diagnostics, notamment les produits CS-Protect Hydrogel et MEDUSA sur les marchés mondiaux.
Les fonds seront alloués pour soutenir le déploiement commercial de CS-Protect Hydrogel, poursuivre la recherche et développement, étendre les opérations et obtenir l'approbation de l'EPA américaine pour le produit désinfectant intelligent MEDUSA. Les parties avancent dans la due diligence finale et les négociations de l'accord définitif, avec pour objectif une clôture dans les semaines à venir.
CS Diagnostics Corp. (OTCQB:CSDX) hat ein Absichtsschreiben von SAN ART CAPITAL SAS für ein geplantes 5-Millionen-Dollar Eigenkapitaldarlehen im Austausch gegen Vorzugsaktien der Serie C erhalten. Die Finanzierungsvereinbarung zielt darauf ab, die Produktion und Vermarktung der Vermögenswerte von CS Diagnostics, insbesondere der Produkte CS-Protect Hydrogel und MEDUSA, auf den globalen Märkten zu unterstützen.
Die Mittel werden verwendet, um den kommerziellen Rollout von CS-Protect Hydrogel zu unterstützen, weitere Forschung und Entwicklung voranzutreiben, operative Erweiterungen durchzuführen und die US-Umweltschutzbehörde EPA-Zulassung für das intelligente Desinfektionsprodukt MEDUSA zu erhalten. Die Parteien befinden sich in der abschließenden Due-Diligence-Phase und Verhandlungen über die endgültige Vereinbarung mit dem Ziel eines Abschlusses in den kommenden Wochen.
- Secured $5 million equity loan commitment
- Funding to support commercial rollout of two key products
- Strategic financing structure minimizes shareholder dilution
- Capital allocation includes EPA approval process advancement
- Deal still subject to final due diligence and definitive agreement
- Company requiring external funding for operations and product development
- Preferred stock issuance may impact existing shareholders' rights
CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.
The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets.
Strategic Purpose:
The intended use of funds will be allocated to support the commercial rollout of CS- Protect Hydrogel further R&D, operational expansions, and U.S. EPA approval for its Smart Disinfectant Product MEDUSA. The parties will proceed with final due diligence and definitive agreement negotiations with the goal of closing the transaction in the coming weeks.
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"This funding agreement will mark a significant milestone in strengthening our financial foundation and aligning with a strategic financial capability. It will allow us to confidently advance through key regulatory stages and operates in several markets while preserving shareholder value and minimizing dilution."
About CS Diagnostics Corp (CSDX)
CS Diagnostics Corp is a biotechnology company focused on the development of cutting-edge diagnostics and therapeutic delivery technologies. Its flagship products, CS Protect-Hydrogel and MEDUSA are designed to meet critical unmet needs in patient care and environmental protection.
About SAN ART CAPITAL SAS
SAN ART CAPITAL SAS http://sanartcapital.com is a Colombia-based private investment firm supporting emerging companies across innovative sectors. The firm partners with high-potential ventures to provide strategic funding and long-term growth capital.
Forward-Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks and uncertainties and other factors.
For further information please visit: https://csdcorp.us/ or email: media@csdcorp.us.
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
FAQ
What is the value of the loan agreement between CS Diagnostics (CSDX) and SAN ART CAPITAL?
How will CSDX use the $5 million loan proceeds?
What products will benefit from CSDX's new funding agreement?
When is the CSDX loan agreement expected to close?
What type of shares will CSDX issue for the $5 million loan?
